Difference between revisions of "Bevacizumab-bvzr (Zirabev)"
m |
m |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 14: | Line 14: | ||
*[[Cervical cancer]] | *[[Cervical cancer]] | ||
*[[Cholangiocarcinoma]] | *[[Cholangiocarcinoma]] | ||
| − | *[[ | + | *[[Colorectal cancer]] |
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| Line 20: | Line 20: | ||
*[[Hepatocellular carcinoma]] | *[[Hepatocellular carcinoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| − | *[[ | + | *[[Malignant pleural mesothelioma]] |
*[[Neuroendocrine tumor]] | *[[Neuroendocrine tumor]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| Line 34: | Line 34: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2019-06-28: Approved ''(Based on REFLECTIONS B7391003)'' |
==Also known as== | ==Also known as== | ||
| + | *'''Code names:''' PF-06439535 | ||
*'''Brand name:''' Zirabev | *'''Brand name:''' Zirabev | ||
| Line 51: | Line 52: | ||
[[Category:Cervical cancer medications]] | [[Category:Cervical cancer medications]] | ||
[[Category:Cholangiocarcinoma medications]] | [[Category:Cholangiocarcinoma medications]] | ||
| − | [[Category: | + | [[Category:Colorectal cancer medications]] |
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| Line 57: | Line 58: | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
| − | [[Category: | + | [[Category:Malignant pleural mesothelioma medications]] |
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
Revision as of 12:55, 25 May 2024
Note: this is a biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication.
General information
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Carcinoma of unknown primary
- Anaplastic glioma
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Colorectal cancer
- Esophageal cancer
- Follicular lymphoma
- Glioblastoma
- Hepatocellular carcinoma
- Melanoma
- Malignant pleural mesothelioma
- Neuroendocrine tumor
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic NET
- Renal cell carcinoma
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
- Endometrial cancer
- Vascular sarcoma
History of changes in FDA indication
- 2019-06-28: Approved (Based on REFLECTIONS B7391003)
Also known as
- Code names: PF-06439535
- Brand name: Zirabev
- Drugs
- Intravenous medications
- Neutral
- Anti-VEGF antibodies
- Carcinoma of unknown primary medications
- Anaplastic glioma medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Colorectal cancer medications
- Esophageal cancer medications
- Follicular lymphoma medications
- Glioblastoma medications
- Hepatocellular carcinoma medications
- Melanoma medications
- Malignant pleural mesothelioma medications
- Neuroendocrine tumor medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Pancreatic NET medications
- Renal cell carcinoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Endometrial cancer medications
- Vascular sarcoma medications
- FDA approved in 2019
- Biosimilars